Procedure: Biospecimen Collection Procedure: Computed Tomography Drug: Dabrafenib Mesylate Procedure: Echocardiography Procedure: Electrocardiogram Biological: Ipilimumab Procedure: Multigated Acquisition Scan Biological: Nivolumab Other: Quality-of-Life Assessment Drug: Trametinib Dimethyl Sulfoxide Condition or diseaseĬlinical Stage III Cutaneous Melanoma AJCC v8 Clinical Stage IV Cutaneous Melanoma AJCC v8 Metastatic Melanoma Recurrent Melanoma Unresectable Cutaneous Melanoma It is not yet known whether treating patients with ipilimumab and nivolumab followed by dabrafenib and trametinib is more effective than treatment with dabrafenib and trametinib followed by ipilimumab and nivolumab. Dabrafenib and trametinib may block tumor growth by targeting the BRAFV600 gene. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This phase III trial studies how well initial treatment with ipilimumab and nivolumab followed by dabrafenib and trametinib works and compares it to initial treatment with dabrafenib and trametinib followed by ipilimumab and nivolumab in treating patients with stage III-IV melanoma that contains a mutation known as BRAFV600 and cannot be removed by surgery (unresectable).
0 Comments
Leave a Reply. |